INTS Stock Overview
A clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Intensity Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.14 |
| 52 Week High | US$11.44 |
| 52 Week Low | US$2.07 |
| Beta | 0 |
| 11 Month Change | -7.65% |
| 3 Month Change | -25.94% |
| 1 Year Change | 46.05% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -47.32% |
Recent News & Updates
Shareholder Returns
| INTS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.9% | -10.5% | -2.1% |
| 1Y | 46.0% | 12.7% | 29.7% |
Return vs Industry: INTS exceeded the US Biotechs industry which returned 13.6% over the past year.
Return vs Market: INTS exceeded the US Market which returned 29.6% over the past year.
Price Volatility
| INTS volatility | |
|---|---|
| INTS Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INTS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: INTS's weekly volatility has decreased from 16% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 6 | Lew Bender | www.intensitytherapeutics.com |
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Intensity Therapeutics, Inc. Fundamentals Summary
| INTS fundamental statistics | |
|---|---|
| Market cap | US$43.38m |
| Earnings (TTM) | -US$16.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.7x
P/E RatioIs INTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INTS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$16.26m |
| Earnings | -US$16.26m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.18 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did INTS perform over the long term?
See historical performance and comparison